ArticleMetabolic brain disease2021
Effects of safflower yellow on cholesterol levels in serum and brain tissue of APP/PS1 mice.
Article in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- A Novel Weight Loss Mechanism of Hydroxysafflor Yellow A in Obese Mice: Involvement of Immune Inflammation via Prkcd, Btk, and Vav1 Genes in Adipose Tissue.Current pharmaceutical biotechnology · 2026Article
- Endothelial delivery of simvastatin by LRP1-targeted nanoparticles ameliorates pathogenesis of alzheimer's disease in a mouse model.Alzheimer's research & therapy · 2025Article
- Oil Content and Fatty Acid Composition of Safflower (Foods (Basel, Switzerland) · 2025Article
- Pharmacological actions and applications of safflower flavonoids.Frontiers in nutrition · 2025Review
- Article
- Connecting the Dots Between Hypercholesterolemia and Alzheimer's Disease: A Potential Mechanism Based on 27-Hydroxycholesterol.Frontiers in neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is an aggressive neurodegenerative disease associated with cognitive decline, memory, language, and visual-spatial coordination disorders that eventually lead to complete loss of basic function. Hypercholesterolemia plays an important role in the pathogenesis of AD and its related diseases. Safflower yellow (SY) is a natural chalcone compound isolated from safflower, which has the effect of antioxidation and weight loss. Previous studies have shown that SY has a significant improvement in learning and memory in various AD model animals. In the early stage of proteomic technology, we found that the cholesterol synthesis rate-limiting enzyme Mevalonate decarboxylase (MVD) was abnormally high in dementia rats, and the expression level of MVD decreased after SY treatment. We speculated that SY may improve the learning and memory ability of AD mice by affecting cholesterol metabolism. The purpose of this study was to evaluate the effect of SY on regulating cholesterol metabolism and improving dementia. The area of amyloid-β (Aβ) plaque in the brain of APP/PS1 mice and various blood biochemical and molecular biological indexes was detected. Through behavioral experiments, we found that APP/ PS1 mice had significant learning and memory impairment compared with wild type mice(P < 0.01). SY (30 mg/kg) treatment for 1 month can significantly improve the learning and memory ability of APP/PS1 mice (P < 0.01). Our results showed that SY decreased serum Total cholesterol (TC) and Triglyceride (TG) and increased the level of High-density lipoprotein (HDL). HE staining obscured that SY affect the changes of liver tissue in APP/PS1 mice (P < 0.05 and P < 0.01). We found that SY reduced the expression of MVD and Apolipoprotein E (APOE4) in the cortex (P < 0.05 and P < 0.01). In summary, SY can effectively control cholesterol in serum and brain and change the degeneration of liver tissue. SY improves Alzheimer's disease by lowering serum, cortex and cortical cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.